Henrietta Lacks’s Family Seeks Compensation

Family members of Lacks, the donor behind the widely used HeLa cell line, are planning to sue Johns Hopkins University.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, EMWSeveral family members of Henrietta Lacks, the unwitting donor of tumor cells developed into the widely used HeLa cell line, say they were never compensated for the cells. They are now planning to sue Johns Hopkins University, which developed the cell line without Lacks’s permission several decades ago, according to The Baltimore Sun.

“Everyone else is making funds off of Henrietta’s cells,” Lacks’s grandson, Ron Lacks, told the Sun. “I am sure my grandmother is up in heaven saying, ‘Well, what about my family?’”

Johns Hopkins told the newspaper that the institution had never patented nor profited from the cells.

The Lacks story was documented in a book, The Immortal Life of Henrietta Lacks, which highlighted how the paucity of informed consent affected her family. In 2013, family members worked out a deal with the National Institutes of Health for the appropriate sharing of the HeLa genome with researchers. At the time, journalist Rebecca Skloot, who wrote The Immortal Life, told The Scientist that commercialization was discussed during negotiations between the Lackses and the NIH, but that science ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies